CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on September 12, 2024, 14 new employees were awarded restricted stock units (RSUs) for an aggregate of 44,000 shares of common stock. The RSUs were granted pursuant to the Company’s 2019 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Board of Directors in August 2019 under Nasdaq Listing Rule 5635(c)(4).

RSUs for an aggregate of 9,000 shares vest over four years, with 25% of the RSUs vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the grantee’s continued service through each applicable vesting date. RSUs for an aggregate of 14,000 shares vest over four years, with 25% of the RSUs vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting quarterly over three years thereafter, subject to the grantee’s continued service through each applicable vesting date. RSUs for an aggregate of 18,000 shares vest over three years, with 33.33% of the RSUs vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting quarterly over two years thereafter, subject to the grantee’s continued service through each applicable vesting date. RSUs for 2,000 shares vest over two years, with 50% of the RSUs vesting on each of the first two anniversaries of the applicable vesting commencement date, subject to the grantee’s continued service through each applicable vesting date. RSUs for 1,000 shares vest over two years, with 50% of the RSUs vesting on the first anniversary of the applicable vesting commencement date, and the balancing vesting quarterly over the following year thereafter, subject to the grantee’s continued service each applicable vesting date.

CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the equity grants. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240913883690/en/